RT Journal Article
SR Electronic
T1 Comparative Cohort Study of Post-Acute Covid-19 Infection with a Nested, Randomized Controlled Trial of Ivabradine for Those With Postural Orthostatic Tachycardia Syndrome (The COVIVA Study)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.25.23289110
DO 10.1101/2023.04.25.23289110
A1 Saunders, David
A1 Arnold, Thomas B.
A1 Lavender, Jason M.
A1 Bi, Daoqin
A1 Alcover, Karl
A1 Hellwig, Lydia D.
A1 Leazer, Sahar T
A1 Mohammed, Roshila
A1 Markos, Bethelhem
A1 Perera, Kanchana
A1 Shaw, Dutchabong
A1 Kobi, Priscilla
A1 Evans, Martin
A1 Mains, Autumn
A1 Tanofsky-Kraff, Marian
A1 Goguet, Emilie
A1 Mitre, Edward
A1 Pratt, Kathleen P
A1 Dalgard, Clifton L
A1 Haigney, Mark C
YR 2023
UL http://medrxiv.org/content/early/2023/04/26/2023.04.25.23289110.abstract
AB Background: Significant clinical similarities have been observed between the recently Described ‘Long-Haul’ COVID-19 (LHC) syndrome, Postural Orthostatic Tachycardia Syndrome (POTS) and Inappropriate Sinus Tachycardia (IST). Shared symptoms include light-headedness, palpitations, tremulousness, generalized weakness, blurred vision, chest pain, dyspnea, “brain-fog”, and fatigue. Ivabradine is a selective sinoatrial node blocker FDA-approved for management of tachycardia associated with stable angina and heart failure not fully managed by beta blockers. In our study we aim to identify risk factors underlying LHC, as well as the effectiveness of ivabradine in controlling heart rate dysregulations and POTS/IST related symptoms.Methods/Design: A detailed prospective phenotypic evaluation combined with multi-omic analysis of 200 LHC volunteers will be conducted to identify risk factors for autonomic dysfunction. A comparator group of 50 volunteers with documented COVID-19 but without LHC will be enrolled to better understand the risk factors for LHC and autonomic dysfunction. Those in the cohort who meet diagnostic criteria for POTS or IST will be included in a nested prospective, randomized, placebo-controlled trial to assess the impact of ivabradine on symptoms and heart rate, assessed non-invasively based on physiologic response and ambulatory electrocardiogram. Additionally, studies on catecholamine production, mast cell and basophil degranulation, inflammatory biomarkers, and indicators of metabolic dysfunction will be measured to potentially provide molecular classification and mechanistic insights.Discussion: Optimal therapies for dysautonomia, particularly associated with LHC, have yet to be defined. In the present study, ivabradine, one of numerous proposed interventions, will be systematically evaluated for therapeutic potential in LHC-associated POTS and IST. Additionally, this study will further refine the characteristics of the LHC-associated POTS/IST phenotype, genotype and transcriptional profile, including immunologic and multi-omic analysis of persistent immune activation and dysregulation. The study will also explore and identify potential endotheliopathy and abnormalities of the clotting cascade.Trial registration: ClinicalTrials.gov, ID:NCT05481177 Registered on 29 July 2022.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05481177Funding StatementThis study is funded by the Defense Health Agency to the Uniformed Services University (Cooperative Agreement with The Metis Foundation) Award # HU00012120090".Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Uniformed Services University of the Health Sciences Institutional Review Board in June 2022 and registered with clinicaltrials.gov as NCT05481177.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript